Dr. Michael J. Pishvaian
Claim this profileSibley Memorial Hospital
Studies Pancreatic Cancer
Studies Cancer
14 reported clinical trials
34 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
BRCA1 positive
BRCA2 positive
2Cancer
Stage IV
Stage III
locally advanced
Affiliated Hospitals
Clinical Trials Michael J. Pishvaian is currently running
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
More about Michael J. Pishvaian
Clinical Trial Related3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Michael J. Pishvaian has experience with
- Pembrolizumab
- Oxaliplatin
- Fluorouracil
- Olaparib
- Irinotecan
- Nivolumab
Breakdown of trials Michael J. Pishvaian has run
Pancreatic Cancer
Cancer
Colorectal Cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael J. Pishvaian specialize in?
Michael J. Pishvaian focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Michael J. Pishvaian currently recruiting for clinical trials?
Yes, Michael J. Pishvaian is currently recruiting for 5 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Michael J. Pishvaian has studied deeply?
Yes, Michael J. Pishvaian has studied treatments such as Pembrolizumab, Oxaliplatin, Fluorouracil.
What is the best way to schedule an appointment with Michael J. Pishvaian?
Apply for one of the trials that Michael J. Pishvaian is conducting.
What is the office address of Michael J. Pishvaian?
The office of Michael J. Pishvaian is located at: Sibley Memorial Hospital, Washington, District of Columbia 20016 United States. This is the address for their practice at the Sibley Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.